Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 11/20 | 0.48 |
| ▸ | PTPN2 | P17706 | 9/20 | 0.44 |
| ▸ | CDC25B | P30305 | 9/20 | 0.44 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.42 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 5/20 | 0.42 |
| ▸ | PTPN6 | P29350 | 3/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | HPD | P32754 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11925104 | 0.87 | PTPN1 (0.48) | PTPN1PTPN2CDC25BPARP15PARP10 | |
| SCHEMBL20369242 | 0.87 | PTPN1 (0.48) | PTPN1PTPN2CDC25BPARP15PARP10 | |
| Netoglitazone SCHEMBL29361540 | 0.82 | FFAR1 (0.55) | PTPN1PTPN2CDC25BPARP15PARP10 | |
| Netoglitazone SCHEMBL29434827 | 0.82 | FFAR1 (0.55) | PTPN1PTPN2CDC25BPARP15PARP10 | |
| Netoglitazone SCHEMBL20125596 | 0.82 | FFAR1 (0.55) | PTPN1PTPN2CDC25BPARP15PARP10 | |
| Netoglitazone SCHEMBL29355960 | 0.82 | FFAR1 (0.55) | PTPN1PTPN2CDC25BPARP15PARP10 | |
| Netoglitazone SCHEMBL20125595 | 0.82 | FFAR1 (0.55) | PTPN1PTPN2CDC25BPARP15PARP10 | |
| Netoglitazone SCHEMBL142658 | 0.82 | FFAR1 (0.55) | PTPN1PTPN2CDC25BPARP15PARP10 | |
| Netoglitazone SCHEMBL29355957 | 0.82 | FFAR1 (0.55) | PTPN1PTPN2CDC25BPARP15PARP10 | |
| Netoglitazone SCHEMBL8877880 | 0.81 | FFAR1 (0.54) | PTPN1PTPN2CDC25BPARP15PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180194732-A1 | MULTI-API LOADING PRODRUGS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-07-12 | — | — | US | disclosed |
| EP-2655314-B1 | MULTI-API LOADING PRODRUGS | ALKERMES PHARMA IRELAND LTD (IE) | 2018-02-07 | — | — | EP | disclosed |
| US-20160024011-A1 | Multi-API Loading Prodrugs | ALKERMES PHARMA IRELAND LTD (IE) | 2016-01-28 | — | — | US | disclosed |
| WO-2012088441-A1 | MULTI- API LOADING PRODRUGS | ALKERMES, INC. (US) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024011-A1 | Multi-API Loading Prodrugs | AADAC, PAICS, ABCG2 | PTPN1 4102/4885PTPN2 4261/4885CDC25B 1014/4885 |
| US-20180194732-A1 | MULTI-API LOADING PRODRUGS | AADAC, PAICS, ABCG2 | PTPN1 4102/4885PTPN2 4261/4885CDC25B 1014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.